5-ARI Use Before, After Diagnosis Significantly Reduced Bladder Cancer-Specific Death 

Share this content:
Study data indicated that pre- and post-diagnostic use of alpha-blockers was not associated with death from bladder cancer.
Study data indicated that pre- and post-diagnostic use of alpha-blockers was not associated with death from bladder cancer.

Use of 5-alpha-reductase inhibitors (5-ARIs) is associated with a lower risk of dying from bladder cancer among men newly diagnosed with the malignancy, researchers reported at the 33rd European Association of Urology Congress in Copenhagen, Denmark.

In a study of 10,720 men newly diagnosed with bladder cancer during 1997 to 2012, first author Ville J. Mäkelä, a medical student at the University of Tampere in Finland, and colleagues found that 5-ARI use before diagnosis and after diagnosis was associated with a significant 15% and 22% decreased risk of bladder cancer-specific death, respectively, compared with non-use. Results also showed that pre- and post-diagnostic use of alpha-blockers was not associated with death from bladder cancer. The investigators included alpha-blockers in their study to account for possible confounding by indication, such as concomitant BPH, for which both alpha-blockers and 5-ARIs are prescribed.

The study supports the role of androgens and benefits of 5-alpha-reductase inhibition in the progression of bladder cancer, the investigators concluded.

The study consisted of 3208 5-ARI users (1328 before bladder cancer diagnosis and 1880 after diagnosis), 6603 alpha-blocker users (2353 before diagnosis and 4250 after diagnosis), and 5090 non-users of either medication class.

The men who used 5-ARIs before and after diagnosis had a median age of 78 and 75 years, respectively. The men who used alpha-blockers before after diagnosis had a median age of 76 and 74 years. Non-users had a median age of 70 years. In all groups, the majority of tumors were localized.

Reference

Mäkelä VJ, Kotsar A, Tammela TL, Murtola TJ. Bladder cancer survival in men using 5-alpha-reductase inhibitors. Data presented at the 33rd European Association of Urology Congress in Copenhagen, Denmark.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs